Alivus Life Sciences Limited (BOM:543322)
India · Delayed Price · Currency is INR | Market Cap | 168.26B +47.2% |
| Revenue (ttm) | 25.90B +7.9% |
| Net Income | 6.03B +21.7% |
| EPS | 49.03 +21.6% |
| Shares Out | n/a |
| PE Ratio | 28.17 |
| Forward PE | 22.14 |
| Dividend | 5.00 (0.36%) |
| Ex-Dividend Date | Sep 1, 2026 |
| Volume | 1,817 |
| Open | 1,390.00 |
| Previous Close | 1,383.40 |
| Day's Range | 1,361.75 - 1,390.00 |
| 52-Week Range | 830.00 - 1,495.30 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 1,432.25 (+4.52%) |
| Est. Earnings | Oct 30, 2026 |
About Alivus Life Sciences
Alivus Life Sciences Limited develops and manufactures active pharmaceutical ingredients in India, the United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China, and Australia. It offers various APIs, such as amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, solifenacin, atovaquone, etoricoxib, dapagliflozin, and sitagliptin for therapeutic areas, including cardiovascular, central nervous system, diabetes, oncology, urology, and pain management, as well as anti-fungal, anti-histaminic, anti-acne, anti-e... [Read more]
Financial Performance
In fiscal year 2026, Alivus Life Sciences's revenue was 25.52 billion, an increase of 6.91% compared to the previous year's 23.87 billion. Earnings were 5.64 billion, an increase of 16.24%.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for 543322 stock is "Strong Buy." The 12-month stock price target is ₹1,432, which is an increase of 4.52% from the latest price.
News
Alivus Life Sciences Transcript: Q1 26/27
Q1 FY 2027 delivered 6.4% revenue growth, strong margin expansion, and robust non-GPL performance, offsetting a sharp GPL decline. Guidance remains for 10%-12% revenue growth and 30%-32% EBITDA margin for FY 2027, with H2 expected to be stronger.
Alivus Life Sciences Quarterly report: Q1 2027
Alivus Life Sciences has published its Q1 2027 quarterly earnings report on July 30, 2026.
Alivus Life Sciences Slides: Q1 2027
Alivus Life Sciences has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 30, 2026.
Alivus Life Sciences Transcript: Q4 25/26
Revenue and profitability grew strongly in FY 2026, driven by non-GPL and CDMO segments, margin expansion, and disciplined cost management. CapEx is fully funded internally, with new capacity and backward integration expected to support future growth.
Alivus Life Sciences Quarterly report: Q4 2026
Alivus Life Sciences has published its Q4 2026 quarterly earnings report on May 14, 2026.
Alivus Life Sciences Slides: Q4 2026
Alivus Life Sciences has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 14, 2026.
Alivus Life Sciences Transcript: Q3 25/26
Record Q3FY26 revenue and margins were driven by strong CDMO recovery, new launches, and operational efficiencies. Capacity expansions are on track, with high single-digit revenue growth and 30%-32% margins guided for FY26. Cash flow and balance sheet remain robust.
Alivus Life Sciences Quarterly report: Q3 2026
Alivus Life Sciences has published its Q3 2026 quarterly earnings report on January 22, 2026.
Alivus Life Sciences Slides: Q3 2026
Alivus Life Sciences has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on January 22, 2026.
Alivus Life Sciences Transcript: Q2 25/26
Q2 FY 2026 saw 16% YoY revenue growth to INR 588 crore, with gross and EBITDA margins rising to 57.7% and 33%, respectively. Non-GPL and new product launches drove growth, while CDMO and GPL are set for H2 recovery. CapEx is below plan, but expansion projects and cash reserves remain strong.
Alivus Life Sciences Quarterly report: Q2 2026
Alivus Life Sciences has published its Q2 2026 quarterly earnings report on November 6, 2025.
Alivus Life Sciences Slides: Q2 2026
Alivus Life Sciences has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 6, 2025.